Want to see SE:ONCOZ full AI Analyst Report?

OncoZenge AB (ONCOZ) Price & Analysis

0 Followers

ONCOZ Stock Chart & Stats

kr5.51

kr0.40(6.64%)

At close: Mar 06 4:00 PM EST

kr5.51

kr0.40(6.64%)

Day’s Range― - ―

52-Week Rangekr3.10 - kr8.58

Previous CloseN/A

Volume9.67K

Average Volume (3M)62.72K

Market Cap

kr88.05M

Enterprise Valuekr108.32

Total Cash (Recent Filing)kr749.00K

Total Debt (Recent Filing)kr7.50M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding25,936,514

10 Day Avg. Volume49,616

30 Day Avg. Volume62,720

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.83

Revenue Forecast (FY)kr5.00M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthRevenue more than doubled from the prior year, indicating that BupiZenge is generating greater commercial activity from a small base. If this trajectory continues, expanding sales could improve operating leverage and provide a stronger foundation for funding development and commercialization.

Positive Gross ProfitPositive gross profit shows that current revenue generates value above direct product costs, even though operating expenses remain far too high. This provides a foundation for future margin improvement if sales scale and the company can control its broader development and operating cost base.

Focused Product And Partnering ModelThe company has a clearly defined pharmaceutical focus rather than a broad, diffuse product portfolio. Concentrating development and commercialization around BupiZenge may help direct limited resources toward one identifiable clinical need and support future direct sales or licensing opportunities.

Bears Say

Large Recurring LossesThe scale of ongoing losses is substantially larger than current revenue, demonstrating that the business has not yet reached economic sustainability. Continued losses can consume funding needed for development and commercialization, while making future earnings improvement dependent on major revenue growth or cost reductions.

Negative Equity And Elevated LeverageNegative equity indicates that liabilities exceed the recorded asset base and materially limits financial flexibility. Debt alongside this deficit increases reliance on external funding and leaves less capacity to absorb setbacks, support investment, or sustain operations without additional capital.

Heavy Cash BurnThe company is consuming substantial cash relative to its revenue scale, confirming that operations are not yet self-funding. Although free cash flow improved versus 2025, continued negative cash generation can require repeated external financing and constrain the pace of product development.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

3M ago

8LY

ONCOZ FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was kr3.10 and its highest was kr8.58 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is kr88.05M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Nov 11, 2026 which is in 49 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on Aug 27, 2026. The company reported -kr0.337 earnings per share for the quarter.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 25,936,514 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -kr0.337 in its last earnings report. Following the earnings report the stock price went down -12.845%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in SE:ONCOZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).